目的观察优化缺血后适应(IPoC)术式在急性ST段抬高型心肌梗死(STEMI)患者行直接经皮冠状动脉介入治疗(PPCI)术中对心肌缺血再灌注损伤(MIRI)的影响及意义,探索最佳缺血后适应术式。方法选择2018年6月—2020年3月在青岛市第八人民医院心...目的观察优化缺血后适应(IPoC)术式在急性ST段抬高型心肌梗死(STEMI)患者行直接经皮冠状动脉介入治疗(PPCI)术中对心肌缺血再灌注损伤(MIRI)的影响及意义,探索最佳缺血后适应术式。方法选择2018年6月—2020年3月在青岛市第八人民医院心内科住院诊断为STEMI并行PPCI术患者150例,随机分为对照组(50例)、IPoC组(50例)及优化IPoC组(50例)。对照组进行常规PCI治疗;IPoC组在开通梗死相关血管(IRA)后,给予常规缺血后适应处理,再置入支架;优化IPoC组在开通IRA后,给予优化缺血后适应处理,再置入支架。比较三组患者血清CTnT、NT-ProBNP、Hs-CRP水平,术中再灌注心律失常发生率,术后24 h心电图ST段回落比例,心脏超声LVEF等指标,及术后主要不良心血管事件发生率。结果术后CTnT、NT-ProB⁃NP、Hs-CRP水平,术中再灌注心律失常发生率,术后24 h ST段回落比例,心功能恢复等方面,优化IPoC组及IPoC组均明显优于对照组(P<0.01),且优化IPoC组优于IPoC组(P<0.05)。结论在STEMI患者PPCI术中,优化缺血后适应术式可以明显减轻再灌注损伤,缩小心肌梗死面积,减少再灌注心律失常,减轻炎症反应,改善心功能及心室重构,起到很好的心脏保护作用。展开更多
Background It.s an effective treatment to implement percutaneous coronary intervention in acute myocardial infarction patients,which rapidly achieve coronary reperfusion. However,many patients with no-reflow,leading t...Background It.s an effective treatment to implement percutaneous coronary intervention in acute myocardial infarction patients,which rapidly achieve coronary reperfusion. However,many patients with no-reflow,leading to cardiovascular events,even sudden death. Bivalirudin has been used in anticoagulant therapy in PCI,which was characterized by rapid onset,strong anticoagulant effect and good safety. The HORIZONS-AMI study showed that bivalirudin reduced the risk of bleeding and death after PCI compared with heparin and glycoprotein IIb/IIIa antagonists. However,bivalirudin increased the risk of acute stent rethrombosis compared to unfractionated heparin and glycoprotein Ⅱb/Ⅲa antagonists. Therefore,the use of bivalirudin in emergency PCI was worth exploring. EUROMAX trial prompted that the patients who underwent emergency PCI and received intravenous use of bivalirudin during transit,might reduce the risk of bleeding. But there were few studies about bivalirudin on the effects of coronary reperfusion. This study was designed to investigate the effects of bivalirudin on coronary blood flow in patients with AMI and the safety of the drug. Methods All 120 AMI patients were divided into treatment group(n=60)and control group(n=60)according to random number method 1:1. In the treatment group,after coronary angiography and before PCI,the intravenous injection of bivalirudin(0.75mg/kg)was proportional,and then the intravenous maintenance was continued(1.75 mg·kg-1·h-1)for 5 h. In the control group,after coronary angiography and before PCI,intravenous injection of tirofiban(10 μg/kg)and unfractionated heparin(100 U/kg),followed by continuous intravenous injection of tirofiban(0.75 μg·kg-1·min-1)for 24 h. The TIMI blood flow classification,corrected TIMI frame number,TIMI myocardial perfusion grade(TMPG),Cardiac ultrasound parameters,serum NT-ProBNP and hs-CRP were recorded in the two groups before and after PCI. Major cardiovascular events(MACE),bleeding event,etc. were recorded. Results The ratio of coronary bl展开更多
文摘目的观察优化缺血后适应(IPoC)术式在急性ST段抬高型心肌梗死(STEMI)患者行直接经皮冠状动脉介入治疗(PPCI)术中对心肌缺血再灌注损伤(MIRI)的影响及意义,探索最佳缺血后适应术式。方法选择2018年6月—2020年3月在青岛市第八人民医院心内科住院诊断为STEMI并行PPCI术患者150例,随机分为对照组(50例)、IPoC组(50例)及优化IPoC组(50例)。对照组进行常规PCI治疗;IPoC组在开通梗死相关血管(IRA)后,给予常规缺血后适应处理,再置入支架;优化IPoC组在开通IRA后,给予优化缺血后适应处理,再置入支架。比较三组患者血清CTnT、NT-ProBNP、Hs-CRP水平,术中再灌注心律失常发生率,术后24 h心电图ST段回落比例,心脏超声LVEF等指标,及术后主要不良心血管事件发生率。结果术后CTnT、NT-ProB⁃NP、Hs-CRP水平,术中再灌注心律失常发生率,术后24 h ST段回落比例,心功能恢复等方面,优化IPoC组及IPoC组均明显优于对照组(P<0.01),且优化IPoC组优于IPoC组(P<0.05)。结论在STEMI患者PPCI术中,优化缺血后适应术式可以明显减轻再灌注损伤,缩小心肌梗死面积,减少再灌注心律失常,减轻炎症反应,改善心功能及心室重构,起到很好的心脏保护作用。
基金supported by Qingdao Municipal Health Commission Planning Project(No.2015-WJZD066)
文摘Background It.s an effective treatment to implement percutaneous coronary intervention in acute myocardial infarction patients,which rapidly achieve coronary reperfusion. However,many patients with no-reflow,leading to cardiovascular events,even sudden death. Bivalirudin has been used in anticoagulant therapy in PCI,which was characterized by rapid onset,strong anticoagulant effect and good safety. The HORIZONS-AMI study showed that bivalirudin reduced the risk of bleeding and death after PCI compared with heparin and glycoprotein IIb/IIIa antagonists. However,bivalirudin increased the risk of acute stent rethrombosis compared to unfractionated heparin and glycoprotein Ⅱb/Ⅲa antagonists. Therefore,the use of bivalirudin in emergency PCI was worth exploring. EUROMAX trial prompted that the patients who underwent emergency PCI and received intravenous use of bivalirudin during transit,might reduce the risk of bleeding. But there were few studies about bivalirudin on the effects of coronary reperfusion. This study was designed to investigate the effects of bivalirudin on coronary blood flow in patients with AMI and the safety of the drug. Methods All 120 AMI patients were divided into treatment group(n=60)and control group(n=60)according to random number method 1:1. In the treatment group,after coronary angiography and before PCI,the intravenous injection of bivalirudin(0.75mg/kg)was proportional,and then the intravenous maintenance was continued(1.75 mg·kg-1·h-1)for 5 h. In the control group,after coronary angiography and before PCI,intravenous injection of tirofiban(10 μg/kg)and unfractionated heparin(100 U/kg),followed by continuous intravenous injection of tirofiban(0.75 μg·kg-1·min-1)for 24 h. The TIMI blood flow classification,corrected TIMI frame number,TIMI myocardial perfusion grade(TMPG),Cardiac ultrasound parameters,serum NT-ProBNP and hs-CRP were recorded in the two groups before and after PCI. Major cardiovascular events(MACE),bleeding event,etc. were recorded. Results The ratio of coronary bl
